|
Mar 11
|
PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study
|
|
Mar 11
|
Is Johnson & Johnson (JNJ) the Best Low Risk Stock to Buy In 2025?
|
|
Mar 11
|
Genmab says J&J not exercising option on HexaBody-CD38
|
|
Mar 11
|
Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success
|
|
Mar 11
|
J&J and Protagonist’s icotrokinra scores in Phase IIb UC study
|
|
Mar 11
|
Genmab sinks as J&J opts not to develop Darzalex successor; stock upgraded
|
|
Mar 10
|
Are High-Yield Dividend Stocks Best for Income-Focused Investors?
|
|
Mar 10
|
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out
|
|
Mar 10
|
How Exxon Mobil, Johnson & Johnson, And Cogent Communications Can Put Cash In Your Pocket
|
|
Mar 10
|
Johnson & Johnson's Ulcerative Colitis Drug Hits Key Trial Goals, Stock Rises
|
|
Mar 10
|
Zacks Investment Ideas feature highlights: Coca-Cola, Philip Morris and Johnson & Johnson
|
|
Mar 10
|
Zacks Investment Ideas feature highlights: Gilead Sciences and Johnson & Johnson
|
|
Mar 10
|
Health Canada authorizes LAZCLUZE® (lazertinib) in combination with RYBREVANT® (amivantamab) as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer
|
|
Mar 10
|
Icotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patients
|
|
Mar 9
|
Is Johnson & Johnson (JNJ) the Best Performing Dividend Stock to Buy Now?
|
|
Mar 8
|
Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis
|
|
Mar 8
|
Buy Gilead Sciences (GILD) Stock at 52-Week Highs?
|
|
Mar 7
|
JNJ Halts Development of Depression Drug Over Efficacy Concerns
|
|
Mar 7
|
J&J drops Phase III MDD programme due to lack of efficacy
|
|
Mar 7
|
Jim Cramer on Johnson & Johnson (JNJ): ‘This Stock Has Been a Horse!’
|